-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Two new products from the company have received drug production registration approvals.
Category:
Time：2019-01-08
The hydrochloride ambroxol injection in three-in-one polypropylene (PP) plastic ampoules—available in 4 ml: 30 mg, 2 ml: 15 mg, and 1 ml: 7.5 mg—and the tirofiban hydrochloride sodium injection in glass bottles (250 ml and 100 ml)—both developed by the company over a period of five years—have obtained drug production registration approvals from the National Medical Products Administration.
Recently, the ambroxol hydrochloride injection—available in three formulations packaged in combined polypropylene (PP) plastic ampoules (including 4 ml: 30 mg, 2 ml: 15 mg, and 1 ml: 7.5 mg)—and the tirofiban hydrochloride sodium injection—available in glass bottles (250 ml and 100 ml)—both developed by the company over a period of five years, have received drug production registration approvals from the National Medical Products Administration.
According to information obtained from the company’s Drug Research Institute, Ambroxol Hydrochloride Injection belongs to Category 6 of original chemical drugs and is used for the treatment of respiratory diseases. Tirofiban Hydrochloride Sodium Injection also belongs to Category 6 of original chemical drugs; it is a cardiovascular medication indicated for the treatment of patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS).
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license